Results 61 to 70 of about 5,781 (240)

Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount [PDF]

, 2014
Background: Targeted radionuclide therapy with high-energy beta-emitters is generally considered suboptimal to cure small tumours (90Y, 177Lu or 213Bi, accounting for the radionuclide specific activities (SAs), the tumour absorbed doses and tumour (radio)
Blois, E. (Erik) de, Boerman, O.C. (Otto), Breeman, W.A.P. (Wouter), Chan, H.S. (Ho Sze), Jong, M. (Marion) de, Kolenc-Peitl, P. (Petra), Konijnenberg, M. (Mark), Laverman, P. (Peter), Melis, M.L. (Marleen)   +8 more
core   +2 more sources

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

Endocrine Connections, 2019
In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide ...
G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, S Cannavò   +10 more
doaj   +1 more source

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +1 more source

Other Radiopharmaceuticals for Imaging GEP‐NET [PDF]

, 2015
In GEP‐NETs, especially the catecholamine and serotonin biosynthetic pathways are upregulated. Therefore, increased biosynthesis of these specific amines in GEP‐NETs enables imaging with specific amine precursors.
Brouwers, Adrienne, de Vries, E. G. E., Dierckx, Rudi, Elsinga, Philip H., Fiebrich, Helle Brit, Kema, Ido, Koopmans, K P, Links, Thera, Walekamp, A M E   +8 more
core   +1 more source

Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice

Journal of Cancer Research and Practice
Objective: The current study aimed to investigate the basic principles and clinical applications, including the selection of proper candidates, follow-up strategies, and radiation protection issues relating to peptide receptor radionuclide therapy (PRRT).
Mei-Fang Cheng, Chih-Chieh Yen, Jeng-Shiun Du, Yu-Li Chiu, Ming-Huang Chen, Hui-Jen Tsai, I-Chen Wu, Hueng-Yuan Shen, Ruoh-Fang Yen, Li-Tzong Chen, On Behalf of Taiwan Neuroendocrine Tumor Society and Taiwan Society of Nuclear Medicine   +10 more
doaj   +1 more source

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source

Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

BMC Cancer, 2020
Background There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally, the aim of these treatments has been to reduce the tumor load; referred to as objective response (OR).
Espen Thiis-Evensen, Amalie Christine Poole, Hong-Thien Thi Nguyen, Jon Sponheim   +3 more
doaj   +1 more source

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source

Clinical Implications of Ki‐67 Index, Grade and Hormonal Changes in Pancreatic Neuroendocrine Tumors: Insights Into Tumor Heterogeneity Based on Primary and Secondary Lesions

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background Pancreatic neuroendocrine tumors (PanNETs) show heterogeneity, including temporal shifts in proliferation and hormone production; however, their clinical implications remain uncertain. Methods This retrospective study included 114 patients with metastatic or recurrent PanNETs at Kyushu University Hospital.
Masatoshi Murakami, Nao Fujimori, Kazuhide Matsumoto, Keijiro Ueda, Kohei Nakata, Masafumi Nakamura, Takeo Yamamoto, Yoshinao Oda, Tetsuhide Ito, Yoshihiro Ogawa   +9 more
wiley   +1 more source

Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT

EJNMMI Physics, 2020
Background Dead time may affect the accuracy of quantitative SPECT (QPSECT), and thus of dosimetry. The aim of this study was to quantify the effect of dead time on 177Lu-QSPECT and renal dosimetry following peptide receptor radionuclide therapy (PRRT ...
Alessandro Desy, Guillaume F. Bouvet, Andrea Frezza, Philippe Després, Jean-Mathieu Beauregard   +4 more
doaj   +1 more source